Ginkgo biloba for prevention of dementia: a randomized controlled trial.
Ginkgo biloba for prevention of dementia: a randomized controlled trial.
复制标题
DOI：
10.1001/jama.2008.683
复制
发表时间：
2008-11-19
影响因子：
120.7
通讯作者：
Furberg, Curt D.
中科院分区：
文献类型：
--
作者：
DeKosky, Steven T.;Williamson, Jeff D.;Fitzpatrick, Annette L.;Kronmal, Richard A.;Ives, Diane G.;Saxton, Judith A.;Lopez, Oscar L.;Burke, Gregory;Carlson, Michelle C.;Fried, Linda P.;Kuller, Lewis H.;Robbins, John A.;Tracy, Russell P.;Woolard, Nancy F.;Dunn, Leslie;Snitz, Beth E.;Nahin, Richard L.;Furberg, Curt D.
银杏因其对记忆和认知的潜在影响而被广泛使用。迄今为止，缺乏足够的临床试验来测试银杏叶对痴呆症发病率的影响。在认知正常和轻度认知障碍（MCI）的老年人中，确定银杏叶与安慰剂相比在降低全因痴呆和阿尔茨海默病（AD）发病率方面的有效性。2000年至2008年在美国5个学术医学中心进行的随机、双盲、安慰剂对照临床试验，中位随访时间为6.1年。3069名75岁或以上的社区志愿者，在研究开始时认知正常（n=2587）或MCI（n=482），每6个月评估一次痴呆事件。每日两次剂量的120 mg银杏叶提取物（n=1545）或安慰剂（n=1524）。由专家小组共识确定的痴呆和AD事件。523名患者发生痴呆（246名接受安慰剂治疗，277名接受银杏叶治疗），其中92%的痴呆病例被归类为可能或可能的AD，或伴有脑血管疾病证据的AD。脱落率和失访率较低（6.3%），两组的不良反应特征相似。分配到银杏叶组的参与者的总体痴呆率为3.3/100人年，安慰剂组为2.9/100人年。与安慰剂相比，银杏叶治疗全因痴呆的风险比（HR）为1.12（95%置信区间[CI]，0.94-1.33; P=.21），AD为1.16（95% CI，0.97-1.39; P=.11）。银杏叶对MCI参与者进展为痴呆的比率也没有影响（HR，1.13; 95% CI，0.85-1.50; P= 0.39）。在这项研究中，银杏叶120毫克，每天两次，对降低认知正常的老年人或MCI患者的痴呆或AD发病率的总体发病率无效。
Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G biloba on dementia incidence are lacking. To determine effectiveness of G biloba vs placebo in reducing the incidence of all-cause dementia and Alzheimer disease (AD) in elderly individuals with normal cognition and those with mild cognitive impairment (MCI). Randomized, double-blind, placebo-controlled clinical trial conducted in 5 academic medical centers in the United States between 2000 and 2008 with a median follow-up of 6.1 years. Three thousand sixty-nine community volunteers aged 75 years or older with normal cognition (n=2587) or MCI (n=482) at study entry were assessed every 6 months for incident dementia. Twice-daily dose of 120-mg extract of G biloba (n=1545) or placebo (n=1524). Incident dementia and AD determined by expert panel consensus. Five hundred twenty-three individuals developed dementia (246 receiving placebo and 277 receiving G biloba) with 92% of the dementia cases classified as possible or probable AD, or AD with evidence of vascular disease of the brain. Rates of dropout and loss to follow-up were low (6.3%), and the adverse effect profiles were similar for both groups. The overall dementia rate was 3.3 per 100 person-years in participants assigned to G biloba and 2.9 per 100 person-years in the placebo group. The hazard ratio (HR) for G biloba compared with placebo for all-cause dementia was 1.12 (95% confidence interval [CI], 0.94–1.33; P=.21) and for AD, 1.16 (95% CI, 0.97–1.39; P=.11). G biloba also had no effect on the rate of progression to dementia in participants with MCI (HR, 1.13; 95% CI, 0.85–1.50; P=.39). In this study, G biloba at 120 mg twice a day was not effective in reducing either the overall incidence rate of dementia or AD incidence in elderly individuals with normal cognition or those with MCI.
登录
查看更多内容
影响因子：
3.6
作者：
BECKER, JT;BOLLER, F;MCGONIGLEGIBSON, KL
通讯作者：
MCGONIGLEGIBSON, KL
影响因子：
4.8
作者：
Maurer, K;Ihl, R;Frolich, L
通讯作者：
Frolich, L
影响因子：
11
作者：
Lopez, OL;Becker, JT;Kuller, LH
通讯作者：
Kuller, LH
影响因子：
--
作者：
Chui, HC;Mack, W;Jagust, WJ
通讯作者：
Jagust, WJ
DOI：
10.1159/000106721
发表时间：
1994-05-01
期刊：
DEMENTIA
影响因子：
--
作者：
ERKINJUNTTI, T
通讯作者：
ERKINJUNTTI, T